Nectar Lifesciences Limited announced its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The Board of Directors noted, decided, and approved these results in a meeting held on January 23, 2026, which commenced at 3:00 PM IST and concluded at 4:30 PM IST. The company has completed the sale of its Pharma Business (API and Formulation) and Menthol Assets to Ceph Lifesciences Private Limited for a total consideration of ₹127,000.00 lakhs, with a final adjusted consideration of ₹125,398.55 lakhs. A profit of ₹8,815.13 lakhs (net of tax) from this sale has been recognized under exceptional items. The sale of the Pharma Businesses was completed on November 10, 2025, with ₹106,598.55 lakhs received by December 31, 2025, and the balance ₹18,800.00 lakhs receivable. Furthermore, Nectar Lifesciences entered into an agreement on December 20, 2025, to sell its Empty Hard Gelatin Capsule business to Capnest Health Care Private Limited for a consideration of ₹1,990.00 lakhs. This transaction is subject to government approval. In a significant corporate action, the Board had previously approved a buyback proposal on December 3, 2025, for 3,00,00,000 equity shares at ₹27.00 per share, aggregating ₹8,100.00 lakhs. The payment for this buyback was made on January 13, 2026, and the shares were extinguished on January 20, 2026. As these events occurred after the financial reporting date, their impact is not reflected in the results for the quarter ended December 31, 2025. The financial results reflect continuing operations, with figures for discontinued operations (Pharma Business, Menthol Assets, and Capsule Business) presented separately as per Ind AS 105.
